What’s New: In our first take on tonight’s results, we dig into: 1. 4Q25 guidance inline, but no sneak peak into 2026 2. Advertising boosted by programmatic demand 3. No changes in content spending outlook 4. KPop Demon Hunters is a catalyst for licensing acceleration 5. FCF outlook steady as Warner speculation grows
Switch 2, Hello Kitty and Demon Slayer have underlined the success of Japan’s global pop culture influence. In this review, Pelham Smithers discusses whether 2025 will be the peak, or if there more to come. In light of the capital limitations faced by Japanese game developers evident at TGS2025, Pelham thinks further consolidation is likely and suggests three likely scenarios.
Moody's Ratings (Moody's) affirmed the ratings of Edwards Lifesciences Corporation (Edwards) including the Baa2 senior unsecured notes and Baa2 senior unsecured bank credit facilities. At the same time, we revised the outlook to positive from stable. The rating affirmation reflects our view that E...
A director at Edwards Lifesciences Corp sold 4,114 shares at 79.461USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.